Video Series

Experts explore the efficacy and safety profiles of elacestrant, an oral selective estrogen receptor degrader (SERD), and other options for endocrine therapy. The panelists also discuss clinical trial insights, progression-free survival rates, and tolerability, highlighting outcomes and advances in metastatic breast cancer treatment.

Key opinion leaders emphasize the role of coordinated care between dermatologists and oncologists in monitoring and managing adverse events related to immunotherapy in CSCC and BCC.

Dr Pisano shares insights on expanding dermatologists' comfort with immunotherapy through collaborative learning and collective expertise.

Elizabeth Spencer, MD, shares experiences as a caregiver to an adult with eosinophilic esophagitis (EoE), discussing challenges with therapy and insurance, and shedding light on how these experiences also might impact pediatric caregivers.

Elizabeth Spencer, MD, explains how a multidisciplinary team and open communication assist in implementing tailored treatment plans for children with eosinophilic esophagitis (EoE) and offers advice for caregivers of children who are newly diagnosed.

The panelists highlight key takeaways for payors involved in MDS treatment.

Experts discuss how collaborative care drives optimal MDS treatment.

Elizabeth Spencer, MD, explains the role of esophageal dilation in treatment of eosinophilic esophagitis (EoE), highlighting the importance of shared decision-making.

Elizabeth Spencer, MD, discusses the role of proton pump inhibitors (PPIs) in treatment of eosinophilic esophagitis (EoE) in pediatric patients.

Michael D. Shapiro, DO, and Jaime Murillo, MD, discuss the implications of high Lp(a) levels in the US population, racial disparities, and tailored interventions for high-risk groups.

Michael D. Shapiro, DO, and Erin D. Michos, MD, MHS, discuss the disproportionately high Lp(a) levels seen across different demographic groups, and the need for increased screening and treatment to mitigate the risk of cardiovascular disease.

Amy Nguyen Howell, MD, MBA, emphasizes ophthalmologists' crucial role in reducing diabetic macular edema (DME) health disparities.

Trajectory of patient outcomes for those diagnosed with bronchiectasis is explored by Dr Metersky.

A panel of medical experts discuss the shift from intervention to prevention in the management of dry eye disease, as well as perspectives on resource allocation.

Experts provide a perspective on disparities in accessibility and outcomes based on the current socioeconomic landscape in health care.

Medical experts discuss unmet needs surrounding treatment of multiple myeloma.

Experts discuss evolving strategies in ER+/HER2– metastatic breast cancer treatment, combining endocrine and targeted therapies, and leveraging specific mutations for optimal patient outcomes.

Key opinion leaders open a discussion surrounding CLL and SLL, and describing unique characteristics of each disease state.

Richard Adler, MD, FACS, Assistant Professor of Ophthalmology at the Wilmer Eye Institute, Johns Hopkins Institute, and Director of Ophthalmology Services at Belcara Health, discusses the critical unmet needs in Dry Eye Disease (DED) therapies and explores the potential impact of new agents in addressing these challenges.

A panel of experts explore desmoid tumor clinical characteristics, heterogeneity, and diagnostic complexities for optimal treatment strategies.

Medical professionals discuss strategies and best practices for recognizing and mitigating immunotherapy toxicities through multidisciplinary collaboration and use of monitoring technology.

The panel emphasizes the role of multidisciplinary tumor boards in optimizing oncology care in nonmelanoma skin cancers.

Therapeutic and financial considerations of EVT are explored by a medical expert.

An expert panel unpacks challenges in implementing bispecific therapies for operational excellence.

Dr Haumschild leads a discussion highlighting key care team members shaping the bispecific therapy decision-making processes.

A panel of medical experts break down the pathophysiology and current treatment landscape surrounding Ph+ ALL.

Amy Nguyen Howell, MD, MBA, highlights health equity issues and racial disparities in the prevalence and treatment of diabetic macular edema and emphasizes the influence of social determinants of health aspects on patient outcomes.